Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Airaksinen MM, Saano V, Steidel E, Juvonen H, Huhtikangas A, Gynther J (1984) Binding of ?-carbolines and tetrahydroisoquinolines by opiate receptors of the ?-type. Acta Pharmacol Toxicol 55: 380?385
Banerjee AK, Falkai PG, Savidge M (1989) Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J 65: 358?361
Celada P, Artigas F (1993) Plasma 5-hydroxyindole acetic acid as an indicator of monoamine oxidase A inhibition in rat brain and peripheral tissues. J Neurochem 61: 2191?2198
Cheng AVT, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, Edwardson JA, Perry RH, Perry EK (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 106: 50?55
Collins MA, Nijm WP, Borge GF, Teas G, Goldfarb C (1979) Dopamine related tetrahydroisoquinolines: significant urinary excretion by alcoholics after alcohol consumption. Science 206: 1184?1186
Cummings JL (1992) Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatr Neuropsychol Behav Neurol 5: 144?150
Damasio AR, Antunes JL, Macedo C (1971) Psychiatric aspects in parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry 34: 502?507
Dostert P, Strolin Benedetti M, Dordain G (1988) Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases. J Neural Transm 74: 61?74
Dostert P, Strolin Benedetti M, Dordain G, Vernay D (1989) Enantiomeric composition of urinary salsolinol in parkinsonian patients after Madopar. J Neural Transm [P-D Sect] 1: 269?78
Dostert P, Strolin Benedetti M, Bellotti V, Allievi C, Dordain G (1990) Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjects. J Neural Transm [Gen Sect] 81: 215?223
Gerlach M, Klaunzer N, Pruntek H (1986) Determination of L-dopa and 3-O-methyl dopa in human plasma by extraction using C18 cartridges followed by high performance liquid Chromatographic analysis with electrochemical detection. J Chromatogr 380: 379?385
Gjerris A, Werdelin L, Rafaelsen O, Ailing C, Christensen NJ (1987) CSF dopamine increased in depression: CSF dopamine, noradrenaline and their metabolites in depressed patients and in controls. J Affect Disord 13: 279?286
Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505?251
Goetz CG, Tanner CM, Klawans HL (1982) Pharmacology of hallucinations induced by long-term drup therapy. Am J Psychiatry 139: 494?497
Hartikainen P, Reinikainen KJ, Soininen H, Sirviö J, Soikkeli R, Riekkinen (1992) Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm [PD-Sect] 4: 53?68
Kaakkula S, Wurtman RJ (1993) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbodopa on extracellular dopamine in the rat striatum. J Neurochem 60: 137?144
Klawans HL (1988) Psychiatric side effects during the treatment of Parkinson's disease. J Neural Transm [Suppl] 27: 117?122
Lauterbach EC (1993) Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 150: 1750
LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M (1992) Markers of dopamine metabolism in Parkinson's disease. Neurology 42: 2111?2117
Mahalanobis PC (1936) On the generalized distance in statistics. Proc Natl Inst Sci India 12: 49?55
Maruyama W, Nakahara D, Dostert P, Takahashi A, Naoi M (1993) Naturally-occuring isoquinolines perturb monoamine metabolism in the brain: studied by in vivo microdialysis. J Neural Transm [Gen Sect] 94: 91?102
Meco G, Bonifati V, Cusimano G, Fabrizio E, Vanacore N (1990) Hallucinations in Parkinson's disease: neuropsychological study. Ital J Neurol Sci 11: 373?379
Meco G, Alessandria A, Bonivati V, Giustini P (1994) Risperidone for hallucinations in levdopa-treated Parkinson's disease patients. Lancet 343: 1370?1371
Melamed E, Hefti F (1984) Mechanism of action of short- and long-term L-dopa treatment. Adv Neurol 40: 149?170
Minami M, Takahashi T, Maruyama W, Takahashi A, Dostert P, Nagatsu T, Naoi M (1992) Inhibition of tyrosine hydroxylase by R and S enantiomers of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydro-isoquinoline. J Neurochem 58: 2097?2101
Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M (1993) Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Transm [Gen Sect] 92: 125?135
Moser A, Vieregge P, Kömpf D (1993) Cerebrospinal fluid dopamine metabolites levels after treatment with deprenyl in Parkinson's disease. In: Felgenhauer K, Holzgraefe M, Prange HW (eds) CNS barriers and modern CSF diagnostics. VCH publishers, New York, pp 427?429
Moser A, Scholz J, Siebecker F (1995a) HPLC assay for quantitating salsolinol in the urine of patients with Parkinson's disease. Biol Chem Hoppe-Seyler 376: 132
Moser A, Scholz J, Nobbe F, Vieregge P, Böhme V, Bamberg H (1995b) Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J Neurol Sci 131: 183?189
Naoi M, Maruyama W, Sasuga S, Deng Y, Dostert P, Ohta S, Takahashi T (1994) Inhibition of type A monoamine oxidase by 2(N)-methyl-6,7-dihydroxyisoquinolinium ions. Neurochem Int 25: 475?481
Naoi M, Dostert P, Yoshida M, Nagatsu T (1993) N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins. Adv Neurol 60: 212?217
Nausieda PA, Glantz R, Weber B, Baum R, Klawans HL (1984) Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 40: 271?277
Origitano T, Hannigan J, Collins MA (1981) Rat brain salsolinol and blood-brain barrier. Brain Res 224: 446?451
Perry EK, Marshall E, Thompson P, McKeith IG, Collerton G, Fairbairn AF, Ferrier IN, Irving D, Perry RH (1993) Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm [PD-Sect] 6: 167?177
Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson's disease. Mov Disord 5: 239?242
Pierce PA, Peroutka SJ (1988) Antagonism of 5-hydroxytryptamine-2 receptor-mediated phosphatidyl-inositol turnover by D-lysergic acid diethylamide. J Pharmacol Exp Ther 247: 918?925
Rondot P, de Recondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 40: 259?269
Sandier M, Bonham Carter SW, Hunter KR, Stern GM (1973) Tetrahydroisoquinoline alkaloides: in vivo metabolite of L-dopa in man. Nature 241: 439?443
Stammel W, Thomas H (1991) Interaction of tetrahydroisoquinoline alkaloids with opiat receptors in the rat brain. Biol Chem Hoppe-Seyler 372: 909?910
Stammel W, Thomas H (1993) A simple and rapid method for the seperation of the (R)- and (S)-enantiomers of the tetrahydroisoquinoline alkaloid salsolinol by high performanceliquid chromatography. Analyt Lett 26: 2513?2524
Standaert DG, Stern MB (1993) Update on the management of Parkinson's disease. Contemp Clin Neurol 77: 169?183
Strolin Benedetti M, Dostert P, Carminati P (1989) Influence of food intake on the enantiometric composition of urinary salsolinol in man. J Neural Transm 78: 43?51
Yoshida M, Ogawa M, Suzuki K, Nagatsu T (1993) Parkinsonism produced by tetrahydroisoquinoline or the analogues. Adv Neurol 60: 207?211